Adicet Bio, Inc.
ACETAdicet Bio is a clinical-stage biotechnology company focused on the discovery and development of allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.
Table of contents
Earnings
Next report
Aug 6, 2026 (In 3 weeks)Competitors
By market cap
By revenue growth
Profile
Adicet Bio is a clinical-stage biotechnology company focused on the discovery and development of allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company utilizes a proprietary platform to engineer "off-the-shelf" chimeric antigen receptor (CAR) T cell candidates derived from unrelated donor blood, designed to provide durable activity without inducing graft-versus-host disease. Their core value proposition lies in a rapid, cost-efficient manufacturing process that enables on-demand treatment and potential outpatient administration.
A clinical-stage innovator in the allogeneic cell therapy space, specifically leveraging Vδ1 gamma delta T cells to differentiate from traditional alpha-beta T cell and NK cell approaches.
Questions, answered.
- What is Adicet Bio, Inc.'s market cap?
- Adicet Bio, Inc. (ACET) has a market capitalization of $83.6M and trades on NASDAQ.
- Who are Adicet Bio, Inc.'s competitors?
- Adicet Bio, Inc.'s key competitors include Allogene Therapeutics, Inc., Nkarta, Inc., Gilead Sciences, Inc., and others. These companies compete in similar markets and product categories.
- Who does Adicet Bio, Inc. partner with?
- Adicet Bio, Inc.'s notable partners include Regeneron Pharmaceuticals, Inc., CRISPR Therapeutics AG, Twist Bioscience Corporation, and others.
- What subsidiaries does Adicet Bio, Inc. have?
- Adicet Bio, Inc.'s subsidiaries include Adicet Bio Israel, Ltd..
- Where is Adicet Bio, Inc. headquartered?
- Adicet Bio, Inc. is headquartered in United States of America and employs approximately 143 people. It has been publicly traded since 2020.